Instrument overview

AUPHAurinia Pharmaceuticals

StockNasdaqCanadaHealth careEU retail: available
—/10

Not scored: not enough data for a fair comparison.

Factor scores

Quality94 / 100
Trend67 / 100
Stability55 / 100

Percentiles within the peer group (100 = the best of its peers); dividend safety in points.

Main drivers

  • Return on assetssupports the score · percentile 98
  • Return on equitysupports the score · percentile 98
  • Accrualsweighs on the score · percentile 2

Red flags and notes

  • Caution:Earnings quality Accruals or the Beneish M-score are in the watch zone.

Price chart

Interactive chart by TradingView: exchange prices are delayed, crypto and currencies are live.

Key metrics

Valuation

P/E
7.0
P/B
3.6
Market cap (EUR)
€2B

Profitability and debt

Return on equity
66.1%

Dividends

Dividend yield
0.00%
Years of dividend growth
0

Returns and risk

1 day
+1.5%
1 month
+1.2%
1 year
+47.9%
Volatility, 1 yr
37.4%
Max drawdown, 1 yr
−21.8%
Beta
0.60

Ratios from SEC filings and end-of-day prices; returns are price changes without dividends.

News and filings

  • FactA filing (SEC EDGAR) or an exchange notice (Moscow Exchange): the issuer's or the exchange's own statement.
  • Media reportA headline from a named media outlet. We link to it and do not check it.
  • RumourUnconfirmed: the headline itself hedges (“reportedly”, “sources say”, “in talks”), names no publisher, or comes from a news aggregator or an automated republisher.

Source: Filings: U.S. SEC EDGAR. The tone is scored automatically from the headline and can be wrong.

Score changes in the last 12 months

Every published rating and change, logged when it was published (EU Market Abuse Regulation).

DateEventBalancedGrowth · IncomeWarningsPrice at publication
First rating —/10 — · — Caution:Earnings quality Available with Invest Pro

Ratings are rules-based descriptions, valid until the next scoring run (about 06:20 and 21:50 UTC) and the same for every visitor.